الإحصائيات الأساسية
| CIK | 1964979 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Allurion Technologies Inc. - Equity Warrant
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4 |
|
| August 21, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 26 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 26 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the |
|
| August 21, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 18 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 18 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Pro |
|
| August 21, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 27 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 27 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the |
|
| August 21, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 17 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 17 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Pro |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4 |
|
| August 19, 2025 |
Exhibit 10.7 EIGHTH AMENDMENT TO LEASE Legacy Huron, LLC, LESSOR and Allurion Technologies, Inc., LESSEE Reference is hereby made to a Lease dated June 15, 2016, as amended by the “First Amendment” to Lease dated as of November, 2016, as amended by the “Second Amendment” to lease dated March 20, 2017, as amended by the “Third Amendment” to Lease dated June 21, 2017, as amended by the “Fourth Amend |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc. |
|
| August 19, 2025 |
Exhibit 4.4 DESCRIPTION OF SECURITIES The following summary of the material terms of Allurion Technologies, Inc.’s (“Allurion”, the “Company”, “we”, or “our”) securities is not intended to be a complete summary of the rights and preferences of such securities. You are encouraged to read the applicable provisions of Delaware law, Allurion’s certificate of incorporation (“Charter”) and bylaws in the |
|
| August 15, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 25 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 25 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic |
|
| August 15, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 16 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 16 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which fo |
|
| August 15, 2025 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Tra |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 13, 2025 |
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update NATICK, Mass. – August 13, 2025 – Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook • Announced new strategic direction focused on l |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 7, 2025 |
Exhibit 99.1 Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol to IRBs for approval on prospective, multi |
|
| August 7, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 24 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 24 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 7, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 15 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 15 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which fo |
|
| June 18, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Allurion Technologies, Inc. |
|
| June 18, 2025 |
As filed with the Securities and Exchange Commission on June 18, 2025 As filed with the Securities and Exchange Commission on June 18, 2025 Registration No. |
|
| May 20, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 23 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 23 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the |
|
| May 20, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 14 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 14 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectu |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2025 |
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Allurion Reports First Quarter 2025 Financial Results and Provides Business Update NATICK, Mass.—May 14, 2025 — (BUSINESS WIRE) — Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook • Maint |
|
| May 7, 2025 |
CORRESP VIA EDGAR May 7, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 30, 2025 |
As filed with the Securities and Exchange Commission on April 29, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 29, 2025 Registration No. |
|
| April 30, 2025 |
EX-FILING FEES EXHIBIT 107 Form S-3 (Form Type) Allurion Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly |
|
| April 18, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 13 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 13 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa |
|
| April 18, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 22 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 22 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| April 17, 2025 |
Exhibit 10.1 SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT This Second Amendment to Note Purchase Agreement (this “Amendment”), dated as of April 15, 2025, is among Allurion Technologies, Inc., a Delaware corporation (together with its successors and permitted assigns, the “Company”), the purchasers party to the Existing Note Purchase Agreement (as defined below), each, a “Purchaser” and, collective |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 11, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 21 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 21 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| April 11, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 12 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa |
|
| April 10, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 3, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 3, 2025 |
EX-99.1 Exhibit 99.1 Allurion Announces Postponement of Special Meeting of Stockholders Meeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast NATICK, Mass. – April 3, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the “Special Meeting”), o |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commissi |
|
| March 27, 2025 |
List of subsidiaries of Allurion Technologies Holdings, Inc. Exhibit 21.1 Subsidiaries of Allurion Technologies, Inc. Name of Subsidiary Jurisdiction of Incorporation Allurion France SAS France Allurion Middle East Medical Instrument Trading LLC United Arab Emirates Allurion UK Ltd. United Kingdom Allurion Italy,Srl Italy Allurion Spain, Srl Spain Allurion Australia Pty Ltd. Australia Allurion Mexico S. de R.L de C.V. Mexico Allurion Technologies, LLC. Dela |
|
| March 27, 2025 |
Allurion Technologies, Inc. Compensation Recovery Policy. Exhibit 97.1 ALLURION TECHNOLOGIES, INC. COMPENSATION RECOVERY POLICY Adopted as of July 31, 2023 Allurion Technologies, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Per |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41767 Allurion Techno |
|
| March 27, 2025 |
Allurion Technologies, Inc. Insider Trading Policy. Exhibit 19.1 ALLURION TECHNOLOGIES, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Allurion Technologies, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider tra |
|
| March 27, 2025 |
Exhibit 4.4 DESCRIPTION OF SECURITIES The following summary of the material terms of Allurion Technologies, Inc.’s (“Allurion”, the “Company”, “we”, or “our”) securities is not intended to be a complete summary of the rights and preferences of such securities. You are encouraged to read the applicable provisions of Delaware law, Allurion’s certificate of incorporation (“Charter”) and bylaws in the |
|
| March 26, 2025 |
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update NATICK, Mass. |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 24, 2025 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| February 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Comm |
|
| February 21, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT February 19, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $6,107,000 of securities of the Company, |
|
| February 21, 2025 |
Exhibit 99.1 Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline NATICK, Mass., February 19, 2025—(BUSINESS WIRE)—Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement |
|
| February 21, 2025 |
Form of Private Placement Warrant (February 2025). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 21, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| February 21, 2025 |
Exhibit 10.2 SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of February 19, 2025, is made by and among Allurion Technologies, Inc., a Delaware corporation (the “Company”) and the Investor set forth on Schedule I (“Investor”). WHEREAS, the Company desires to sell, and Investor desires to purchase from the Company, shares of its common stock, par value $0.0001 per share (the “Common Stock”) and |
|
| February 21, 2025 |
Form of Common Warrant (February 2025). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 21, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 20 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 20 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| February 21, 2025 |
Exhibit 99.2 Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline NATICK, Mass. – Feb. 20, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and |
|
| February 21, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 11 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa |
|
| February 20, 2025 |
ALLURION TECHNOLOGIES, INC. 900,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-283721 PROSPECTUS SUPPLEMENT (To Prospectus dated December 20, 2024) ALLURION TECHNOLOGIES, INC. 900,000 Shares of Common Stock We are offering 900,000 shares of our common stock to certain accredited investors, at an offering price of $5.23 per share and accompanying common warrant (as defined below). In a concurrent private |
|
| February 14, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 19 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 19 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| February 14, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 10 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa |
|
| February 13, 2025 |
Exhibit 99.1 Allurion Relaunches in France ANSM, the French regulatory authority, clears Allurion to resume sales of the Allurion Balloon Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss February 13, 2025 08:30 AM Eastern Standard Time NATICK, Mass.—(BUSINESS WIRE)—Allurion Technologies, Inc. (“Allurion” or the “Com |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Comm |
|
| January 28, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 9 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commi |
|
| January 28, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms |
|
| January 28, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT January 24, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $7,440,000 of securities of the Company, includ |
|
| January 28, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 18 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 18 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| January 28, 2025 |
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market EX-99.1 Exhibit 99.1 Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market NATICK, Mass. – Jan. 24, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase an |
|
| January 28, 2025 |
Form of Common Warrant (January 2025). EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| January 27, 2025 |
ALLURION TECHNOLOGIES, INC. 1,240,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-283721 PROSPECTUS SUPPLEMENT (To Prospectus dated December 20, 2024) ALLURION TECHNOLOGIES, INC. 1,240,000 Shares of Common Stock We are offering 1,240,000 shares of our common stock to certain accredited investors, at an offering price of $6.00 per share and accompanying common warrant (as defined below). In a concurrent priv |
|
| January 17, 2025 |
Exhibit 99.1 Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024 NATICK, Mass. – Jan. 14, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Invest |
|
| January 17, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 17 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 17 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commi |
|
| January 17, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 8 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part |
|
| January 17, 2025 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of January 14, 2025, is made by and among Allurion Technologies, Inc., a Delaware corporation (the “Company”) and the Investors set forth on Schedule I (the “Investors”). WHEREAS, the Company desires to sell and the Investors desire to purchase from the Company shares of its common stock, par value $0.0001 per share (the “Common Stoc |
|
| January 14, 2025 |
Allurion Technologies, Inc. 11 Huron Drive Natick, MA 01760 Allurion Technologies, Inc. 11 Huron Drive Natick, MA 01760 January 14, 2025 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Re: Allurion Technologies, Inc.—Request for Withdrawal of Registration Statement on Form S-1 (File No. 333-283701) Ladies and Gentlemen: Pursuant to Rule 477 promulgate |
|
| January 13, 2025 |
Form of Series A Common Warrant. Exhibit 4.5 SERIES A COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [ ] Issue Date: [ ], 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| January 13, 2025 |
Table of Contents As filed with the Securities and Exchange Commission on January 13 , 2025. |
|
| January 13, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January , 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| January 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc. |
|
| January 13, 2025 |
Form of Series B Common Warrant. Exhibit 4.6 SERIES B COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [] Issue Date: [], 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder |
|
| January 13, 2025 |
Form of Placement Agency Agreement. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [ ], 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $[ ] of registered securities of the Company, in |
|
| January 8, 2025 |
Exhibit 10.49 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS CONFIDENTIAL, THE DISCLOSURE OF WHICH WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY. OMNIBUS AMENDMENT This Omnibus Amendment, dated as of Ja |
|
| January 8, 2025 |
Exhibit 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| January 8, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation |
|
| January 8, 2025 |
Exhibit 99.4 Allurion Announces Positive Topline Results From AUDACITY Trial At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable safety profile of the Allurion Balloon Fourth and final module of PMA submission including AUDACITY trial data planned for 2025 NATI |
|
| January 8, 2025 |
Exhibit 4.5 COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [] Initial Exercise Date: [], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “ |
|
| January 8, 2025 |
Exhibit 99.2 INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES Page Interim Unaudited Financial Statements as of September 30, 2024 Unaudited Condensed Consolidated Balance Sheets F-2 Unaudited Condensed Consolidated Statements of Operations F-3 Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) F-4 Unaudited Condensed Consolidated Statements of Sto |
|
| January 8, 2025 |
Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES Page Audited Consolidated Financial Statements as of December 31, 2023 Report of Independent Registered Public Accounting Firm (PCAOB ID: 34) F-2 Consolidated Balance Sheets as of December 31, 2023 and 2022 F-3 Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 F-4 Consolidated |
|
| January 8, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January , 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| January 8, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc. |
|
| January 8, 2025 |
Table of Contents As filed with the Securities and Exchange Commission on January 8 , 2025. |
|
| January 8, 2025 |
Form of Placement Agency Agreement. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [ ], 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $[ ] of registered securities of the Company, in |
|
| January 8, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 7 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| January 8, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis includes information that our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The discussion and analysis should be read together with the consolidated financial statements as o |
|
| January 8, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 16 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 16 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic |
|
| January 7, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 15 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 15 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic |
|
| January 7, 2025 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 6 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporatio |
|
| December 31, 2024 |
EX-3.1 2 d924855dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALLURION TECHNOLOGIES, INC. ALLURION TECHNOLOGIES, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Allurion Technologies, Inc. The date of the filing of it |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporatio |
|
| December 31, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 14 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 14 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| December 31, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 5 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part |
|
| December 31, 2024 |
Allurion Technologies, Inc. Announces Reverse Stock Split Exhibit 99.1 Allurion Technologies, Inc. Announces Reverse Stock Split NATICK, Mass., December 24, 2024 (GLOBE NEWSWIRE) – Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per sh |
|
| December 20, 2024 |
As filed with the Securities and Exchange Commission on December 20, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 20, 2024 Registration No. |
|
| December 19, 2024 |
VIA EDGAR December 19, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 19, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Allurion Technologies, Inc. |
|
| December 19, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 12 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| December 19, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 13 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 13 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| December 19, 2024 |
As filed with the Securities and Exchange Commission on December 19, 2024 S-3/A As filed with the Securities and Exchange Commission on December 19, 2024 Registration No. |
|
| December 19, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 4 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part |
|
| December 18, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 10, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc. |
|
| December 10, 2024 |
EX-4.9 Exhibit 4.9 ALLURION TECHNOLOGIES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities an |
|
| December 10, 2024 |
As filed with the Securities and Exchange Commission on December 10, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 10, 2024 Registration No. |
|
| December 10, 2024 |
Form of indenture for senior debt securities and the related form of senior debt security. EX-4.8 Exhibit 4.8 ALLURION TECHNOLOGIES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trus |
|
| December 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Allurion Technologies, Inc. |
|
| December 10, 2024 |
Power of Attorney (included on signature page to this Registration Statement). As filed with the Securities and Exchange Commission on December 9, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 92-2182207 (State or other jurisdiction of incorporation or organiz |
|
| November 14, 2024 |
ALUR / Allurion Technologies Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-alur093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Allurion Technologies, Inc. (Name of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securities) 02008G102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 14, 2024 |
ALUR / Allurion Technologies Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427061d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Allurion Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shar |
|
| November 14, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 3 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus” |
|
| November 14, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 12 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prosp |
|
| November 14, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 11 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospe |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 13, 2024 |
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update NATICK, Mass.- November 13, 2024 - (BUSINESS WIRE) - Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highligh |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 5, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 11 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| November 5, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 2 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part |
|
| November 5, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 10 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which |
|
| November 4, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 4, 2024 |
Execution Version Exhibit 10.1 REVENUE INTEREST FINANCING AGREEMENT among ALLURION TECHNOLOGIES, LLC and RTW MASTER FUND, LTD., RTW INNOVATION MASTER FUND, LTD., and RTW BIOTECH OPPORTUNITIES OPERATING LTD Dated as of October 30, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 34 ARTICLE II REVENUE INTERE |
|
| October 29, 2024 |
424B3 1 d872151d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 5 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 202 |
|
| October 29, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 9 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| October 29, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 10 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form |
|
| October 29, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 1 d872151d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 1 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, th |
|
| October 28, 2024 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 24, 2024 |
SC 13D/A 1 p24-3055sc13da.htm ALLURION TECHNOLOGIES INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934 ALLURION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02008G102 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong, M.D. 40 10th |
|
| October 7, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-279902 PROSPECTUS ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by the selling securityholder identified in this prospectus of up to an aggregate of 65,211,325 shares of common stock, par value $0.0001 per share (“common stock”), of |
|
| October 3, 2024 |
As filed with the Securities and Exchange Commission on October 3, 2024 Registration No. |
|
| October 3, 2024 |
VIA EDGAR October 3, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 30, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on September 30, 2024 Registration No. |
|
| September 30, 2024 |
EXHIBIT 107 Form S-1 (Form Type) Allurion Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Sec |
|
| September 6, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 4 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as supplemented or amended fr |
|
| September 6, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 9 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| September 6, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 8 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 5, 2024 |
Allurion Receives Continued Listing Standards Notice from NYSE Exhibit 99.1 Allurion Receives Continued Listing Standards Notice from NYSE September 5, 2024 NATICK, Mass.-(BUSINESS WIRE)- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 02, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 4, 2024 |
Exhibit 99.1 Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market NATICK, Mass. – Sep. 3, 2024 – Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of D |
|
| August 16, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 8 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| August 16, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 3 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as supplemented or amended fr |
|
| August 16, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 7 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| August 15, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 7 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospec |
|
| August 15, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 6 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospect |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 15, 2024 |
Allurion Receives Continued Listing Standards Notice from NYSE Exhibit 99.1 Allurion Receives Continued Listing Standards Notice from NYSE August 15, 2024 NATICK, Mass.-(BUSINESS WIRE)- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued li |
|
| August 15, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 2 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as suppleme |
|
| August 14, 2024 |
Exhibit 10.6 EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (the "8th Amendment") is made and entered into as of April 3, 2024 (the "Execution Date"), by and between FOURTEEN HURON DRIVE, LLC, a Massachusetts limited liability company ("Landlord''), and ALLURION TECHNOLOGIES, INC., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant arc parties to that certain lease dated |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc. |
|
| August 14, 2024 |
Exhibit 10.7 17 May 2024 Mr. Ojas Buch [***] Re: Conditional Offer of Employment with Allurion Technologies, Inc. Dear Ojas, It is with great pleasure that we offer you the position of Chief Operating Officer with Allurion Technologies, Inc. (the “Company”). You will be reporting to Shantanu Gaur, CEO & Founder, and your anticipated start date is Monday, 3 June 2024. You will work in our Natick, M |
|
| August 13, 2024 |
Exhibit 99.1 Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update Results highlighted by strong sequential revenue growth and record procedure volume NATICK, Mass.- August 13, 2024 - (BUSINESS WIRE) - Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the second quar |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 9, 2024 |
ALUR / Allurion Technologies Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 8, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 6 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| August 8, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 1 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as supplemented or amended fr |
|
| August 8, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 5 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 5, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 5 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| July 5, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 4 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commissio |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 ALLURION TECHNOLOGIES, INC. (formerly known as Allurion Technologies Holdings, Inc.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02008G102 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong, M.D. 40 10th |
|
| July 1, 2024 |
Exhibit 10.1 EXECUTION VERSION SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of June 28, 2024, is made by and among Allurion Technologies, Inc., a Delaware corporation (the “Company”) and the Investors set forth on Schedule I (the “Investors”). WHEREAS, concurrently with this Agreement, the Company is entering into an Underwriting Agreement (as amended or modified from time to time, the “Und |
|
| July 1, 2024 |
Exhibit 99.1 Allurion Announces Pricing of $20 Million Public Offering and Concurrent Private Placement June 28, 2024 NATICK, Mass., June 28, 2024 (BUSINESS WIRE) – Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 p |
|
| July 1, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 20 Issue Date: July 1, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, to subscribe for and purchase f |
|
| July 1, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 3 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| July 1, 2024 |
Exhibit 3.1 ALLURION TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Allurion Technologies, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commissi |
|
| July 1, 2024 |
Form of Private Placement Warrant. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 20 Issue Date: July 1, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, to subscribe for and purchase f |
|
| July 1, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 4 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| July 1, 2024 |
Exhibit 1.1 Execution Version ALLURION TECHNOLOGIES, INC. UNDERWRITING AGREEMENT June 28, 2024 JEFFERIES LLC TD SECURITIES (USA) LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TD SECURITIES (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Introductory. Allurion Technologies, Inc., a Delaware corporati |
|
| June 28, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-280466 PROSPECTUS ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock We are offering 14,406,508 of shares of our common stock and new warrants to purchase up to an aggregate of 14,406,508 shares of our common stock. This prospectus also relates to the offe |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 25, 2024. Registration No. 333- UN ITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 92-2182207 (State or other jurisdiction of incorporation or organiz |
|
| June 26, 2024 |
Exhibit 4.5 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of , 2024, is entered into by and between Allurion Technologies, Inc. a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as Warrant Agent. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant Agreement, the following terms have |
|
| June 26, 2024 |
Exhibit 99.1 Investor Presentation 1 Disclaimer This presentation, the information contained herein and the materials accompanying it (together, this “presentation”) contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the “Company” or “us”) and is provided to the recipients (“you”) of this presentation on the condition that you agree to hold it in stri |
|
| June 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc. |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Allurion Technologies, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State of Incorporation or Organization) (Commission Fil |
|
| June 26, 2024 |
Form of Underwriting Agreement. Exhibit 1.1 ALLURION TECHNOLOGIES, INC. UNDERWRITING AGREEMENT [Date] JEFFERIES LLC TD SECURITIES (USA) LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TD SECURITIES (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Introductory. Allurion Technologies, Inc., a Delaware corporation (the “Company”), propo |
|
| June 26, 2024 |
Exhibit 4.6 [Form of Warrant Certificate] [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW ALLURION TECHNOLOGIES, INC. Incorporated Under the Laws of the State of Delaware CUSIP [ ] Warrant Certificate This Warrant Certificate certifies that, or registered assigns, is the register |
|
| June 25, 2024 |
June 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 25, 2024 |
VIA EDGAR June 26, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 21, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. |
|
| June 21, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on June 2 1 , 2024 Registration No. |
|
| May 31, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on Ma y 31, 2 024 Registration No. |
|
| May 31, 2024 |
EX-FILING FEES EXHIBIT 107 Form S-1 (Form Type) Allurion Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly R |
|
| May 28, 2024 |
Table of Contents CONFIDENTIAL TREATMENT REQUESTED BY ALLURION TECHNOLOGIES, INC. PURSUANT TO 17 CFR 200.83. As confidentially submitted to the Securities and Exchange Commission on May 24, 2024. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES |
|
| May 24, 2024 |
Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 May 24, 2024 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7561 Re: Allurion Technologies, Inc. Draft Registration Statement on Form S-1 Confidentially Submitted on May 24, 2024 CIK No. 0001964979 Ladies and Ge |
|
| May 14, 2024 |
Allurion Reports First Quarter 2024 Financial Results and Provides Business Update ACTIVE/129533855.2 Exhibit 99.1 Allurion Reports First Quarter 2024 Financial Results and Provides Business Update NATICK, Mass.- May 14, 2024 (BUSINESS WIRE)- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the first quarter ended March 31, 2024, and provided a business update. Recent Company |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc. |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 30, 2024 |
ACTIVE/129238067.2 Exhibit 99.1 Allurion Announces Preliminary First Quarter 2024 Results Generated quarter-over-quarter revenue growth and continued growth in procedural volume, while substantially reducing cash burn Company to report full first quarter 2024 financial results on May 14, 2024 NATICK, Mass. – Apr. 30, 2024 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4 |
|
| April 17, 2024 |
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments Exhibit 99.1 Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments • Simplifies capital structure through prepayment of existing term loan • Reduces annual interest expense, providing increased near-term cash flow and operational flexibility • Extends expected cash runway in advance of AUDACITY FDA trial read-out • Strengthens long-term partnership with RTW Inv |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 ALLURION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02008G102 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong, M.D. 40 10th Avenue, Floor 7 New York, New York 10014 (Name, Address |
|
| April 17, 2024 |
EXECUTION VERSION Exhibit 10.2 OMNIBUS AMENDMENT This Omnibus Amendment (this “Amendment”), dated as of April 14, 2024, is among 4010 Royalty Investments ICAV, an Irish collective asset-management vehicle, for and on behalf of its sub-fund, 4010 Royalty Investments Fund 1, and 4010 Royalty Master Fund, LP, a Cayman Islands limited partnership (each and collectively, together with its and their suc |
|
| April 17, 2024 |
Execution Version Exhibit 10.4 FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT This First Amendment to Note Purchase Agreement (this “Amendment”), dated as of April 16, 2024, is among Allurion Technologies, Inc., a Delaware corporation (formerly known as Allurion Technologies Holdings, Inc.) (together with its successors and permitted assigns, the “Company”), the purchasers party to the Existing Note P |
|
| April 17, 2024 |
EXECUTION VERSION Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS CONFIDNETIAL, THE DISCLOSURE OF WHICH WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY. NOTE PURCHASE AGREEMENT This Note Purch |
|
| April 17, 2024 |
Execution Version Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED LETTER AGREEMENT This First Amendment to Amended and Restated Letter Agreement (this “Amendment”), dated as of April 14, 2024, is made by and among Allurion Technologies, Inc. (formerly known as Allurion Technologies Holdings, Inc.), a Delaware corporation (the “Company”), Allurion Technologies, LLC (formerly known as Compute H |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 26, 2024 |
Exhibit 19.1 ALLURION TECHNOLOGIES, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Allurion Technologies, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider tra |
|
| March 26, 2024 |
Exhibit 10.39 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Brendan Gibbons (the “Executive”) and is made effective as of January 29, 2024 (the “Effective Date”) WHEREAS, the Company desires to employ the Executive and the Executive desires to continue to be employed by the Company on the terms |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41767 Allurion Techno |
|
| March 26, 2024 |
List of subsidiaries of Allurion Technologies Holdings, Inc. Exhibit 21.1 Subsidiaries of Allurion Technologies, Inc. Name of Subsidiary Jurisdiction of Incorporation Allurion France SAS France Allurion Middle East Medical Instrument Trading LLC United Arab Emirates Allurion Hong Kong Ltd. Hong Kong Allurion UK Ltd. United Kingdom Allurion Italy,Sri Italy Allurion Spain, Sri Spain Allurion Australia Pty Ltd. Australia Allurion Mexico S. de R.L de C.V. Mexic |
|
| March 26, 2024 |
Exhibit 10.36 TRANSACTION SETTLEMENT AGREEMENT Le présent protocole est conclu entre : (1) ALLURION FRANCE, société par actions simplifiée, immatriculée auprès du Registre du Commerce et des Sociétés de Paris sous le numéro unique d’identification 828 621 383, dont le siège social est situé 6, Boulevard Montmartre – 75009 Paris, France, dûment représentée aux présentes, (2) ALLURION TECHNOLOGIES, |
|
| March 26, 2024 |
Allurion Technologies, Inc. Compensation Recovery Policy. Exhibit 97.1 ALLURION TECHNOLOGIES, INC. COMPENSATION RECOVERY POLICY Adopted as of July 31, 2023 Allurion Technologies, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Per |
|
| March 26, 2024 |
Exhibit 10.37 PROTOCOLE D’ACCORD En date du 12 décembre 2023 (1) BENOIT CHARDON CONSULTING (2) MONSIEUR BENOIT CHARDON (3) ALLURION FRANCE TERMINATION AGREEMENT As of December 12, 2023 (1) BENOIT CHARDON CONSULTING (2) MR BENOIT CHARDON (3) ALLURION FRANCE Le présent protocole est conclu entre : (1) BENOIT CHARDON CONSULTING, société à responsabilité limitée, immatriculée auprès du Registre du Com |
|
| March 21, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,560,431 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 3 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,560,431 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 21, 2024 |
Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance March 21, 2024 NATICK, Mass. |
|
| March 21, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 2 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 15, 2024 |
Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair EX-99.1 Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair NATICK, MA – March 12, 2024 – Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024. "Milena joins the Allurion board during an exciting time in t |
|
| February 14, 2024 |
ALUR / Allurion Technologies Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245287d13sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Allurion Technologies, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (the “Shar |
|
| January 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 8, 2024 |
Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook Generated substantial procedure growth in 2023 driven by best-in-class efficacy of balloon program; prioritizing key investments in strategic markets and digital innovations ahead of FDA milestones NATICK, Mass. |
|
| January 2, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 1 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| January 2, 2024 |
ALLURION TECHNOLOGIES, INC. Up to 56,560,431 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 2 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,560,431 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
|
| December 29, 2023 |
ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 PROSPECTUS ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (“Chardan”) of up to 9,482,468 shares of our common stock, par value $0.0001 per share (“Common Stock”), that have been or may be issued b |
|
| December 29, 2023 |
Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY This AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY, dated as of December 29, 2023 (this “Amendment”), is by and among ALLURION TECHNOLOGIES, LLC, a Delaware limited liability company (the “Borrower”), ALLURION TECHNOLOGIES, INC., a Delaware corporation (the “Parent”), certain Subsidiaries of the Parent party hereto, |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: (December 29, 2023) ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employe |
|
| December 27, 2023 |
Allurion Technologies, Inc. 11 Huron Drive Natick, MA 01760 Allurion Technologies, Inc. 11 Huron Drive Natick, MA 01760 December 27, 2023 VIA EDGAR Conlon Danberg Office of Industrial Applications and Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Allurion Technologies, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-276131 Requested Date: December |
|
| December 26, 2023 |
EX-99.1 2 tm2333707d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Allurion Technologies, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1 |
|
| December 26, 2023 |
ALUR / Allurion Technologies Inc. / CITADEL ADVISORS LLC - SC 13G Passive Investment SC 13G 1 tm2333707d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Allurion Technologies, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (the “Shares”) ( |
|
| December 19, 2023 |
Exhibit 10.1 ChEF PURCHASE AGREEMENT This ChEF PURCHASE AGREEMENT is made and entered into as of December 18, 2023 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Allurion Technologies, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, the parties desire that, upon the terms and subject |
|
| December 19, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc. |
|
| December 19, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on December 19, 2023 Registration No . |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: (December 18, 2023) ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employe |
|
| December 19, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 18, 2023, is by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), Allurion Technologies, Inc., a Delaware corporation (the “Company”). RECITALS The Company and the Investor have entered into that certain Common Stock Purchase Agreement |
|
| December 15, 2023 |
ALLURION TECHNOLOGIES, INC. Up To 56,560,431 Shares of Common Stock 424B3 1 d432702d424b3.htm 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-274564 PROSPECTUS ALLURION TECHNOLOGIES, INC. Up To 56,560,431 Shares of Common Stock This prospectus relates to the resale from time to time by the selling securityholders named in this prospectus (collectively, the “Selling Securityholders”), or their permitted transferees (after the expiratio |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 15, 2023 |
ALLURION TECHNOLOGIES, INC. Up to 56,560,431 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 1 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,560,431 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms |
